Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$173.9MBeat by $4.3M
EPS-$0.43Miss by $0.24
Revenue estimate$169.7M
EPS estimate-$0.19
“This performance gives us the commercial foundation and financial strength to remain intensely focused on growing XDEMVY while strategically investing in our next wave of growth. Together with today's announcement of our agreement to acquire Alkeus Pharmaceuticals, we are building what we believe is one of the most compelling late-stage pipelines, with multiple opportunities to improve patient care and create long-term value.”
Bobak Azamian

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$183.7M
EPS estimate-$1.43

Financials

Q2 2026

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.63B+66.5%
Enterprise value$3.52B+63.1%
P/S6×-1.4×

Profitability

See full
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Segments

By segment

See full
Reportable Segment$173.9M+69.4%

FAQ

When did Tarsus Pharmaceuticals, Inc. report Q2 2026 earnings?
Tarsus Pharmaceuticals, Inc. (TARS) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Tarsus Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
Tarsus Pharmaceuticals, Inc. reported revenue of $173.9M and eps of $-0.43 for Q2 2026.
Did Tarsus Pharmaceuticals, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $169.7M by $4.3M. EPS missed the consensus estimate of $-0.19 by $0.24.
How did Tarsus Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 69.4% from $102.7M a year earlier and eps grew 10.4% from $-0.48.
Where can I find Tarsus Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001819790-26-000060) and the 10-Q periodic report (0001819790-26-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.